Replication FailureOpen accessMedicine· cited by 9

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

Chloe Stanley; Ritwika Mallik; Nausheen Hamid; Friedrich C. Jassil; Victoria Reuven; Tapiwa Ruwona; Samuel James Dicken; Sulmaaz Qamar · 2026 · Nature Medicine

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

A suboptimal clinical response after metabolic and bariatric surgery (MBS) is common and carries considerable health concerns. Here a double-blinded, randomized (1:1), placebo-controlled trial using semaglutide 2.4 mg weekly (BARI-STEP) recruited adult participants at least 1 year after gastric bypass or sleeve gastrectomy with a suboptimal clinical response, defined as less than 20% weight loss from surgery. This was an adjunct to lifestyle intervention with a 500-kcal daily energy deficit. The primary outcome was percentage weight loss after 68-week treatment on an intention-to-treat analysi

Abstract by Chloe Stanley; Ritwika Mallik; Nausheen Hamid; Friedrich C. Jassil; Victoria Reuven; Tapiwa Ruwona; Samuel James Dicken; Sulmaaz Qamar, Nature Medicine (2026) — licensed CC BY 4.0.

Read the full paper (open access)